Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

Author(s)

Picanco-Castro, Virginia ^[1] ; Bonamino, Martin Hernan ^{[2, 3]} ; Ramos, Rodrigo Nalio ^{[4, 5]} ; Guerino-Cunha, Renato L. ^[6] ; Oliveira, Theo Gremen M. ^{[4, 7]} ; Rego, Eduardo M. ^[8]

Affiliation

^[1] Hosp Clin Fac Med Ribeirao Preto Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, Ribeirao Preto, SP - Brazil

^[2] Inst Nacl Canc INCA, Div Pesquisa Expt & Translac, Rio De Janeiro, RJ - Brazil

^[3] Pesquisa & Colecoes Biol Fundacao Oswaldo Cruz VP, Rio De Janeiro, RJ - Brazil

^[4] Fac Med Univ Sao Paulo HCFMUSP, Hosp Clin, Lab Invest Med Patogenese & Terapia Dirigida Onco, Sao Paulo, SP - Brazil

^[5] Inst DOr Ensino & Pesquisa, Sao Paulo, SP - Brazil

^[6] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Imagens Med Hematol & Oncol Clin, Ribeirao Preto, SP - Brazil

^[7] Fundacao Pro Sangue Hemoctr Sao Paulo, Sao Paulo, SP - Brazil

^[8] Hosp Clin Fac Med Ribeirao Preto HCFMRP USP, Ribeirao Preto, SP - Brazil

• Document type: Journal article
• Source: Hematology, Transfusion and Cell Therapy; v. 43, n. 2, p. S54-S63, NOV 2021.
• Web of Science Citations: 0

Abstract

Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended period of preclinical evaluation that demonstrated unprecedented efficacy in this difficult-to-treat patient population. This review article outlines the main preclinical evaluations needed for CAR T cell product development. (C) 2021 Published by Elsevier Espana, S.L.U. on behalf of Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. (AU)

• FAPESP's process: 19/25309-0 - Off-the-shelf engineered NK cells for the treatment of Leukemia and Lymphoma treatment
• Grantee: Virginia Picanço e Castro
• Support Opportunities: Regular Research Grants
• FAPESP's process: 20/07055-9 - Nucleus of Cellular Therapy - NuTeC
• Grantee: Dimas Tadeu Covas
• Support Opportunities: Research Grants - Problem-Oriented Research Centers in São Paulo
• FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
• Grantee: Dimas Tadeu Covas
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC